Jennifer Havlek, Author at Personalis

About Jennifer Havlek

This author has not yet filled in any details.
So far Jennifer Havlek has created 45 blog entries.

7 Jul, 2020

2020 AACR: Quantification of tumor-infiltrating immune cell populations with an augmented transcriptome

2020 AACR: Quantification of tumor-infiltrating immune cell populations with an augmented transcriptome Comprehensive characterization of the tumor and tumor microenvironment (TME) can improve our understanding of tumor progression and treatment outcomes. In particular, quantification of the immune infiltrate has the potential to inform mechanisms of immune escape and predict response to therapy. Standard experimental [...]

7 Jul, 2020

2020 AACR: Precision neoantigen discovery using a pan-predictive machine learning model integrated into ImmunoID NeXT Platform®

2020 AACR: Precision neoantigen discovery using a pan-predictive machine learning model integrated into ImmunoID NeXT Platform® Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Our ImmunoID [...]

7 Jul, 2020

2020 AACR: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy

2020 AACR: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance Loss of heterozygosity (LOH) in the HLA locus is increasingly being recognized as an important mechanism of immune escape and a proposed biomarker for immunotherapy response. Neoantigens that bind to a deleted HLA allele will no longer be presented to [...]

7 Jul, 2020

2020 ASCO: Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck.

2020 ASCO: Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck. Background: The reduced scope, and number of genes profiled by typical liquid biopsy panels can result in missed biomarkers including neoantigens, which may change with treatment, as [...]

7 Jul, 2020

2020 ASCO: Validation of an exome and transcriptome based diagnostic platform enabling clinical cancer therapy selection and emerging composite biomarkers for immunotherapy

2020 ASCO: Validation of an exome and transcriptome based diagnostic platform enabling clinical cancer therapy selection and emerging composite biomarkers for immunotherapy Authors: Juan-Sebstian Saldivar, Jason Harris, Sejal Desai, Erin Ayash, Prateek Tandon, Twinkal Marfatia, Robert Power, Massimo Morra, Manju Chinnappa, Michael James Clark, Rena McClory, Richard Chen; Personalis, Inc., Menlo [...]

25 Jun, 2020

2020 Breast Cancer Summit Presentation

2020 Breast Cancer Summit Presentation Enabling multidimensional tumor immunogenomics for advancing biomarker discovery Christelle Johnson, PhD Senior Field Application Scientist Enabling multidimensional tumor immunogenomics for advancing biomarker discovery Insight into the complex and dynamic interactions between the tumor and immune cells of the microenvironment is essential for cancer immunotherapy translational studies Purpose built [...]

25 Jun, 2020

2020 EACR Virtual Congress: Industry Symposium

2020 EACR Virtual Congress: Industry Symposium Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform Erin Newburn, MS, PhD Director, Field Application Scientist Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform In this presentation, we’ll provide an overview of the [...]

25 Nov, 2019

2019 SITC: Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms

2019 SITC: Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms Checkpoint inhibitor therapy has demonstrated meaningful antitumor activity for many patients, though the majority fail to achieve complete response. Thus, it is of particular interest to identify biomarkers and mechanisms that promote positive response to immunotherapy. In [...]

12 Sep, 2019

Karin Eastham
Gallery
Karin Eastham
Board, People

Karin Eastham

Karin Eastham has served on our board since September 2019. Ms. Eastham has over 35 years of experience in financial and operations management, primarily in life sciences companies. Ms. Eastham serves as a director for 3 additional public biotechnology companies, Nektar Therapeutics, Geron Corporation, and Veracyte, Inc. Her former public directorships include Illumina, Inc., MorphoSys [...]

30 Jul, 2019

Biomarker Challenge #2: Analysis of Complex Data

Biomarker Challenge #2: Analysis of Complex Data More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients. Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The ImmunoID NeXT™ platform investigates key aspects [...]

Previous 123 Next

jhavlek

About Jennifer Havlek